Related Experiment Video
Updated: Jun 8, 2025
05:35
Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
Published on: September 15, 2023
1.4K
Carboplatin dosing in obese patients
Cristina Ramírez-Roig1, Alberto Espuny-Miró1, Raquel Olmos-Jiménez1
1Pharmacy Service, Virgen de la Arrixaca University Clinical Hospital, Murcia, Spain.
Summary
Carboplatin dosing in obese patients showed that using actual body weight led to more toxicity, particularly thrombocytopenia and neutropenia. However, effectiveness in ovarian and lung cancer did not differ significantly between dosing methods.
Area of Science:
- Oncology
- Pharmacology
- Clinical Pharmacy
Background:
- Obesity presents challenges in chemotherapy dosing, particularly for carboplatin.
- Accurate carboplatin dosing is crucial for balancing efficacy and toxicity in obese patients.
- Current clinical practice for carboplatin dosing in obese individuals requires further investigation.
Purpose of the Study:
- To describe carboplatin dosing criteria in obese patients in a general university hospital.
- To evaluate the toxicity associated with different carboplatin dosing criteria.
- To assess the effectiveness of carboplatin treatment based on the dosing criterion used in major oncological diagnoses.
Main Methods:
- An observational, retrospective study of obese patients (BMI ≥ 30 kg/m²) receiving carboplatin between January 2012 and January 2015.
- Data collected included patient characteristics, disease details, carboplatin dosing methods (Calvert's formula with Cockcroft-Gault for GFR), and toxicity (CTCAE v. 4.0).
- Effectiveness was assessed via overall survival and progression-free survival for ovarian and non-small cell lung cancer.
Main Results:
- Carboplatin dosing utilized Calvert's formula with Cockcroft-Gault for GFR estimation, employing actual body weight (ABW) and ideal adjusted body weight (IABW) in similar proportions.
- IABW was more frequently used in patients with higher obesity and diabetes.
- Toxicity, including thrombocytopenia, neutropenia, GOT elevation, hyporexia, and myalgias, was significantly greater when carboplatin was dosed by ABW compared to IABW.
Conclusions:
- Carboplatin dosing in obese patients using ABW was associated with increased toxicity compared to IABW.
- Despite toxicity differences, no statistically significant variations in overall survival or progression-free survival were observed between ABW and IABW dosing groups for ovarian and non-small cell lung cancer.
- The findings suggest a need to carefully consider dosing strategies to mitigate toxicity in obese patients receiving carboplatin, while maintaining treatment effectiveness.
More Related Videos
Related Concept Videos
01:11Renal Failure: Dose Adjustments
67
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
67
01:16Insulin: Dosing Regimen and Adverse Effects
146
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
146
01:15Drug Dosage Regimen: Overview
3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K
01:01Dosage Regimen: Fixed Dose
1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K
01:24Rational Dosage Regimen: Maintenance Dose and Loading Dose
3.9K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
3.9K
01:19One-Compartment Open Model for IV Bolus Administration: General Considerations
164
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
164